Characterization of preclinical Alzheimer’s disease model: spontaneous type 2 diabetic cynomolgus monkeys with systemic pro-inflammation, positive biomarkers and developing AD-like pathology

[1] DeTure MA(2019)The neuropathological diagnosis of Alzheimer’s disease Mol Neurodegener 14 32-36

[2] Dickson DW(2009)Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease Neurobiol Aging 30 1026-68

[3] Price JL(1999)Tangles and plaques in nondemented aging and preclinical Alzheimer’s disease Ann Neurol 45 358-95

[4] McKeel DW(2003)Neuropathology of cognitively normal elderly J Neuropathol Exp Neurol 62 1087-9

[5] Buckles VD(2006)Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans Ann Neurol 59 512-9

[6] Roe CM(2007)Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults Arch Neurol 64 343-18

[7] Xiong C(2023)CSF Aβ(42) and tau biomarkers in cognitively unimpaired Aβ- middle-aged and older APOE ε4 carriers Neurobiol Aging 129 209-3004

[8] Grundman M(2023)Robustness of CSF Aβ42/40 and Aβ42/P-tau181 measured using fully automated immunoassays to detect AD-related outcomes Alzheimers Dement 19 2994-804

[9] Price JL(2012)Clinical and biomarker changes in dominantly inherited Alzheimer’s disease N Engl J Med 367 795-70

[10] Morris JC(2014)Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer’s disease Sci Transl Med 6 226ra30-323

[1] DeTure MA(2019)The neuropathological diagnosis of Alzheimer’s disease Mol Neurodegener 14 32-36

[2] Dickson DW(2009)Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease Neurobiol Aging 30 1026-68

[3] Price JL(1999)Tangles and plaques in nondemented aging and preclinical Alzheimer’s disease Ann Neurol 45 358-95

[4] McKeel DW(2003)Neuropathology of cognitively normal elderly J Neuropathol Exp Neurol 62 1087-9

[5] Buckles VD(2006)Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans Ann Neurol 59 512-9

[6] Roe CM(2007)Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults Arch Neurol 64 343-18

[7] Xiong C(2023)CSF Aβ(42) and tau biomarkers in cognitively unimpaired Aβ- middle-aged and older APOE ε4 carriers Neurobiol Aging 129 209-3004

[8] Grundman M(2023)Robustness of CSF Aβ42/40 and Aβ42/P-tau181 measured using fully automated immunoassays to detect AD-related outcomes Alzheimers Dement 19 2994-804

[9] Price JL(2012)Clinical and biomarker changes in dominantly inherited Alzheimer’s disease N Engl J Med 367 795-70

[10] Morris JC(2014)Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer’s disease Sci Transl Med 6 226ra30-323